MoonLake Immunotherapeutics (MLTX) CMD 2024 summary

Strategic vision and future plans

• Focused on advancing sonelokimab (SLK), a tri-specific nanobody targeting IL-17A and IL-17F, with monthly subcutaneous administration and multi-billion-dollar potential in large inflammatory indications like HS and PsA.

• Expanding clinical programs to include palmoplantar pustulosis (PPP), axial spondyloarthritis (axSpA), and adolescent HS, each with significant market opportunities.

• Operational execution is on track, with phase III trials in HS (VELA-1, VELA-2) and PsA (IZAR-1, IZAR-2) progressing, and additional phase II and III studies in new indications being initiated.

• No current plans for partnerships or M&A; focus remains on independent development and commercialization, with potential optionality considered for 2026–2027 and further guidance expected post-JPM 2025.

• Organization has tripled in size since last year, ensuring sufficient resources for execution.

Financial guidance and catalysts

• Peak sales opportunity for sonelokimab projected at over $8 billion, with HS and PsA as lead drivers and additional contributions from PPP, axSpA, and adolescent HS.

• Raised approximately $750 million since IPO, with a strong cash position of $519.8 million as of June 30, 2024, supporting at least 18 months of runway through key phase III readouts and funding operations through at least the end of 2026.

• 2024 is a year of execution, with multiple studies initiated; major data catalysts expected in 2025–2026, including primary endpoint readouts for HS and PsA and regulatory submissions.

• BLA submission and potential U.S. launch for sonelokimab in HS (adult and adolescent) targeted for 2027.

• Operating expenses are increasing in line with clinical activity, but remain efficient compared to peers and the broader biotech sector.

Clinical development and differentiation

• Sonelokimab has demonstrated high efficacy in phase II trials, with strong responses in HS (HiSCR75, IHS4 100) and PsA (multi-domain outcomes), and is positioned as a potential best-in-class therapy.

• Phase III HS program is on track, with primary endpoint data expected mid-2025; adolescent HS and PPP studies are also underway.

• Differentiation from competitors (notably bimekizumab) based on efficacy, benefit-risk profile, monthly dosing, unique adolescent HS indication, and Nanobody® technology.

• Market research and real-world data show rapid market expansion for HS, with biologic penetration and pricing supporting large commercial potential.

• Innovative imaging and biomarker programs support scientific leadership and potential for new intellectual property, demonstrating efficacy in deep tissue inflammation and multi-domain disease control.